Á lódáil...
Structural reengineering of imatinib to decrease cardiac risk in cancer therapy
Imatinib, a selective, small-molecule tyrosine kinase inhibitor, has life-saving clinical activity in certain cancers, but questions have been raised about the potential for cardiac toxicity through inhibition of its target, ABL kinase. In this issue of the JCI, Fernández et al. describe a novel met...
Na minha lista:
| Príomhúdar: | |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
American Society for Clinical Investigation
2007
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2096446/ https://ncbi.nlm.nih.gov/pubmed/18060025 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI34252 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|